{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:19:08Z","timestamp":1790684348410,"version":"4.1.0"},"reference-count":51,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T00:00:00Z","timestamp":1648339200000},"content-version":"unspecified","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,1,21]]},"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:p>Immunotherapy has fundamentally changed the landscape of cancer treatment. However, only a subset of patients respond to immunotherapy, and a significant portion experience immune-related adverse events (irAEs). In addition, the predictive ability of current biomarkers such as programmed death-ligand 1 (PD-L1) remains unreliable and establishing better potential candidate markers is of great importance in selecting patients who would benefit from immunotherapy. Here, we focus on the role of serum-based proteomic tests in predicting the response and toxicity of immunotherapy. Serum proteomic signatures refer to unique patterns of proteins which are associated with immune response in patients with cancer. These protein signatures are derived from patient serum samples based on mass spectrometry and act as biomarkers to predict response to immunotherapy. Using machine learning algorithms, serum proteomic tests were developed through training data sets from advanced non-small cell lung cancer (Host Immune Classifier, Primary Immune Response) and malignant melanoma patients (PerspectIV test). The tests effectively stratified patients into groups with good and poor treatment outcomes independent of PD-L1 expression. Here, we review current evidence in the published literature on three liquid biopsy tests that use biomarkers derived from proteomics and machine learning for use in immuno-oncology. We discuss how these tests may inform patient prognosis as well as guide treatment decisions and predict irAE of immunotherapy. Thus, mass spectrometry-based serum proteomics signatures play an important role in predicting clinical outcomes and toxicity.<\/jats:p>","DOI":"10.1136\/jitc-2021-003566","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T23:06:53Z","timestamp":1648508813000},"page":"e003566","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":50,"title":["Role of mass spectrometry-based serum proteomics signatures in predicting clinical outcomes and toxicity in patients with cancer treated with immunotherapy"],"prefix":"10.1136","volume":"10","author":[{"given":"Yeonggyeong","family":"Park","sequence":"first","affiliation":[{"name":"Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Jeong","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoonhee","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, NewYork-Presbyterian Queens, Flushing, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, AMITA Health Saint Joseph Hospital Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leeseul","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, AMITA Health Saint Francis Hospital Evanston, Evanston, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Pyo Daniel","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Gyo","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Kwang","family":"Chae","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"key":"2025100313591588000_10.3.e003566.1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1680"},{"key":"2025100313591588000_10.3.e003566.2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00574-0"},{"key":"2025100313591588000_10.3.e003566.3","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41416-018-0207-6","article-title":"Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006","volume":"119","author":"Hamid","year":"2018","journal-title":"Br J Cancer"},{"key":"2025100313591588000_10.3.e003566.4","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30700-9"},{"key":"2025100313591588000_10.3.e003566.5","doi-asserted-by":"crossref","first-page":"S1181","DOI":"10.1016\/j.annonc.2020.08.2284","article-title":"LBA51 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) \u226550%","volume":"31","author":"Brahmer","year":"2020","journal-title":"Ann Oncol"},{"key":"2025100313591588000_10.3.e003566.6","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced Non\u2012small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study","volume":"37","author":"Garon","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025100313591588000_10.3.e003566.7","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-020-00209-0","article-title":"Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors","volume":"8","author":"Bai","year":"2020","journal-title":"Biomark Res"},{"key":"2025100313591588000_10.3.e003566.8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100313591588000_10.3.e003566.9","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2006.069252"},{"key":"2025100313591588000_10.3.e003566.10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21030838","article-title":"Mass spectrometry-based multivariate proteomic tests for prediction of outcomes on immune checkpoint blockade therapy: the modern analytical approach","volume":"21","author":"Grigorieva","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025100313591588000_10.3.e003566.11","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk195"},{"key":"2025100313591588000_10.3.e003566.12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-13-S3-S13"},{"key":"2025100313591588000_10.3.e003566.13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.clinms.2019.09.001","article-title":"Application of protein set enrichment analysis to correlation of protein functional sets with mass spectral features and multivariate proteomic tests","volume":"15","author":"Grigorieva","year":"2020","journal-title":"Clinical Mass Spectrometry"},{"key":"2025100313591588000_10.3.e003566.14","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.21037\/tlcr-20-148","article-title":"Mass spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy","volume":"9","author":"Chae","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"2025100313591588000_10.3.e003566.15","doi-asserted-by":"crossref","first-page":"9545","DOI":"10.1200\/JCO.2020.38.15_suppl.9545","article-title":"Real-world performance of blood-based host immune profiling in first-line immunotherapy treatment in advanced-stage non-small cell lung cancer","volume":"38","author":"Mitchell","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025100313591588000_10.3.e003566.16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0538"},{"key":"2025100313591588000_10.3.e003566.17","doi-asserted-by":"crossref","unstructured":"Xu G , Rice R , Huang H . Abstract 387: Glycoproteomics as a powerful liquid biopsy-based predictor of checkpoint-inhibitor treatment response. 112th Annual Meeting of the American Association for Cancer Research 2021.doi:https:\/\/doi.org\/10.1158\/1538-7445.AM2021-387","DOI":"10.1158\/1538-7445.AM2021-387"},{"key":"2025100313591588000_10.3.e003566.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050753"},{"key":"2025100313591588000_10.3.e003566.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67625-8"},{"key":"2025100313591588000_10.3.e003566.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70162-7"},{"key":"2025100313591588000_10.3.e003566.21","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31826c1155"},{"key":"2025100313591588000_10.3.e003566.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jprot.2012.06.022"},{"key":"2025100313591588000_10.3.e003566.23","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4193-0","article-title":"The serum-based VeriStrat\u00ae test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients","volume":"18","author":"Fidler","year":"2018","journal-title":"BMC Cancer"},{"key":"2025100313591588000_10.3.e003566.24","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1080\/03007995.2020.1790346","article-title":"Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis","volume":"36","author":"Leal","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"2025100313591588000_10.3.e003566.25","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0089"},{"key":"2025100313591588000_10.3.e003566.26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/bjc.2016.387","article-title":"Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy","volume":"116","author":"Grossi","year":"2017","journal-title":"Br J Cancer"},{"key":"2025100313591588000_10.3.e003566.27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2016.11.1870","article-title":"P3.02c-074 evaluation of a pretreatment serum tests for nivolumab benefit in patients with non-small cell lung cancer","volume":"12","author":"Grossi","year":"2017","journal-title":"J Thor Oncol"},{"key":"2025100313591588000_10.3.e003566.28","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1200\/JCO.19.03022","article-title":"Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update","volume":"38","author":"Hanna","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025100313591588000_10.3.e003566.29","unstructured":"Network NCC . Non-Small cell lung cancer (version 2.2020). Available: http:\/\/www.nccn.org\/default.aspx [Accessed 23 Dec 2019]."},{"key":"2025100313591588000_10.3.e003566.30","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0059"},{"key":"2025100313591588000_10.3.e003566.31","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0018"},{"key":"2025100313591588000_10.3.e003566.32","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0768-9"},{"key":"2025100313591588000_10.3.e003566.33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1608069113"},{"key":"2025100313591588000_10.3.e003566.34","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1021\/acs.analchem.9b00776","article-title":"Site-specific glycosylation quantitation of 50 serum glycoproteins enhanced by predictive glycopeptidomics for improved disease biomarker discovery","volume":"91","author":"Li","year":"2019","journal-title":"Anal Chem"},{"key":"2025100313591588000_10.3.e003566.35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jprot.2020.103820","article-title":"PB-Net: automatic peak integration by sequential deep learning for multiple reaction monitoring","volume":"223","author":"Wu","year":"2020","journal-title":"J Proteomics"},{"key":"2025100313591588000_10.3.e003566.36","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e21218","article-title":"Potential role of serum proteome in predicting immune-related adverse events from immune checkpoint inhibitors in non-small cell lung cancer","volume":"39","author":"Kim","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025100313591588000_10.3.e003566.37","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2020-5527","article-title":"Abstract 5527: serum proteomic scores for understanding the mechanisms of immune-related adverse events (irAEs) in non-small cell lung cancer","volume":"80","author":"Davis","year":"2020","journal-title":"Cancer Res"},{"key":"2025100313591588000_10.3.e003566.38","doi-asserted-by":"crossref","first-page":"S407","DOI":"10.1016\/j.jtho.2021.01.675","article-title":"P33.06 utilizing serum proteome to understand response and resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"16","author":"Chae","year":"2021","journal-title":"J Thor Oncol"},{"key":"2025100313591588000_10.3.e003566.39","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025100313591588000_10.3.e003566.40","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2805-3"},{"key":"2025100313591588000_10.3.e003566.41","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9002","article-title":"Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150","volume":"39","author":"Socinski","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025100313591588000_10.3.e003566.42","doi-asserted-by":"crossref","unstructured":"Nam M , Kim L , Cheng W . Abstract 520: potential role of serum proteome in predicting immune-related adverse events from immunotherapy in non-small cell lung cancer. Cancer Res 2021;81520.doi:DOI:10.1200\/JCO.2021.39.15_suppl.e21218","DOI":"10.1158\/1538-7445.AM2021-520"},{"key":"2025100313591588000_10.3.e003566.43","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy269.068","article-title":"Prediction of primary resistance to anti-PD1 therapy (APD1) in second-line NSCLC","volume":"29","author":"Smit","year":"2018","journal-title":"Ann Oncol"},{"key":"2025100313591588000_10.3.e003566.44","first-page":"37","article-title":"The role of proteomic testing in improving prognosis and care planning quality measures for lung cancer","volume":"26","author":"Page","year":"2017","journal-title":"Manag Care"},{"key":"2025100313591588000_10.3.e003566.45","unstructured":"Page RD , Arnaud AM . Precision medicine: estimated clinical and economic outcomes of using a predictive and prognostic biomarker to avoid ineffective therapies in advanced non-small cell lung cancer. the American College of medical quality (ACMQ) annual meeting. Washington DC 2017."},{"key":"2025100313591588000_10.3.e003566.46","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002989"},{"key":"2025100313591588000_10.3.e003566.47","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.201300377"},{"key":"2025100313591588000_10.3.e003566.48","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/jnci\/djab067","article-title":"Wedding of molecular alterations and immune checkpoint blockade: genomics as a matchmaker","author":"Fountzilas","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2025100313591588000_10.3.e003566.49","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954"},{"key":"2025100313591588000_10.3.e003566.50","unstructured":"Medicare clinical laboratory fee schedule (CLFS), 2019. Available: https:\/\/www.cms.gov\/license\/ama?file=\/files\/zip\/21clabq3.zip [Accessed 20 Sep 2021]."},{"key":"2025100313591588000_10.3.e003566.51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17033-7"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-003566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T20:59:29Z","timestamp":1759525169000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-003566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":51,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,28]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1136\/jitc-2021-003566"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-003566","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}